| Nancy Calenda, CRNA | |
|
101 Dudley St, Providence, RI 02905-2401 | |
| (401) 529-4412 | |
| (401) 456-3621 |
| Full Name | Nancy Calenda |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 43 Years |
| Location | 101 Dudley St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285768556 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RNA20109 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kent County Memorial Hospital | Warwick, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Narragansett Bay Anesthesia Llc | 5991774929 | 100 |
News Archive
Researchers from Mount Sinai School of Medicine have found a new mechanism that explains why a certain gene mutation causes craniofrontonasal syndrome (CFNS), a disorder that causes cleft palate and other malformations in the face, brain, and skeleton. Cleft palate affects one of every 1,000 newborns. The research is published in the September 15 issue of Genes & Development.
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.
Kent medical device manufacturer, Bedfont Scientific Ltd., signs a multiyear ODM deal to supply MGC Diagnostics Corporation with its new NObreath®.
Although women are four times more likely than men to develop osteoporosis, or porous bone, one in 12 men also suffer from the disease, which can lead to debilitating - or even life-threatening - fractures, mainly of the spine, hip and wrist.
Many gene therapy-based approaches are in development to combat genetic and other causes of blindness and vision loss, and much can be learned about the safety and effectiveness of these promising new therapies by studying them first in non-human primates before initiating clinical trials, as shown by the results of a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
› Verified 4 days ago
| Entity Name | Narragansett Bay Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861445728 PECOS PAC ID: 5991774929 Enrollment ID: O20040928000003 |
News Archive
Researchers from Mount Sinai School of Medicine have found a new mechanism that explains why a certain gene mutation causes craniofrontonasal syndrome (CFNS), a disorder that causes cleft palate and other malformations in the face, brain, and skeleton. Cleft palate affects one of every 1,000 newborns. The research is published in the September 15 issue of Genes & Development.
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.
Kent medical device manufacturer, Bedfont Scientific Ltd., signs a multiyear ODM deal to supply MGC Diagnostics Corporation with its new NObreath®.
Although women are four times more likely than men to develop osteoporosis, or porous bone, one in 12 men also suffer from the disease, which can lead to debilitating - or even life-threatening - fractures, mainly of the spine, hip and wrist.
Many gene therapy-based approaches are in development to combat genetic and other causes of blindness and vision loss, and much can be learned about the safety and effectiveness of these promising new therapies by studying them first in non-human primates before initiating clinical trials, as shown by the results of a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
› Verified 4 days ago
| Entity Name | Anesthesiology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669409561 PECOS PAC ID: 2264446236 Enrollment ID: O20060128000067 |
News Archive
Researchers from Mount Sinai School of Medicine have found a new mechanism that explains why a certain gene mutation causes craniofrontonasal syndrome (CFNS), a disorder that causes cleft palate and other malformations in the face, brain, and skeleton. Cleft palate affects one of every 1,000 newborns. The research is published in the September 15 issue of Genes & Development.
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.
Kent medical device manufacturer, Bedfont Scientific Ltd., signs a multiyear ODM deal to supply MGC Diagnostics Corporation with its new NObreath®.
Although women are four times more likely than men to develop osteoporosis, or porous bone, one in 12 men also suffer from the disease, which can lead to debilitating - or even life-threatening - fractures, mainly of the spine, hip and wrist.
Many gene therapy-based approaches are in development to combat genetic and other causes of blindness and vision loss, and much can be learned about the safety and effectiveness of these promising new therapies by studying them first in non-human primates before initiating clinical trials, as shown by the results of a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nancy Calenda, CRNA 101 Dudley St, Providence, RI 02905-2401 Ph: (401) 529-4412 | Nancy Calenda, CRNA 101 Dudley St, Providence, RI 02905-2401 Ph: (401) 529-4412 |
News Archive
Researchers from Mount Sinai School of Medicine have found a new mechanism that explains why a certain gene mutation causes craniofrontonasal syndrome (CFNS), a disorder that causes cleft palate and other malformations in the face, brain, and skeleton. Cleft palate affects one of every 1,000 newborns. The research is published in the September 15 issue of Genes & Development.
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.
Kent medical device manufacturer, Bedfont Scientific Ltd., signs a multiyear ODM deal to supply MGC Diagnostics Corporation with its new NObreath®.
Although women are four times more likely than men to develop osteoporosis, or porous bone, one in 12 men also suffer from the disease, which can lead to debilitating - or even life-threatening - fractures, mainly of the spine, hip and wrist.
Many gene therapy-based approaches are in development to combat genetic and other causes of blindness and vision loss, and much can be learned about the safety and effectiveness of these promising new therapies by studying them first in non-human primates before initiating clinical trials, as shown by the results of a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
› Verified 4 days ago
Brian F Girard, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy Street, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Peter W Wolferseder, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy Street, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Marie A Mills, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 593 Eddy Street, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Beth Vanpraag, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy Street, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Paulette Champion, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Angela Thomas, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy Street, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Garrick Mark Whitlock, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 825 Chalkstone Ave, Providence, RI 02908 Phone: 401-456-2000 |